Drug intelligence / Profile preview

exemestane + tremelimumab

Development stage: Unknown
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

exemestane + tremelimumab is a combination therapy for advanced hormone receptor-positive breast cancer. Exemestane is an aromatase inhibitor that blocks estrogen synthesis, while tremelimumab is a fully human IgG2 monoclonal antibody targeting CTLA-4, which acts as an immune checkpoint inhibitor to stimulate anti-tumor immune responses. The combination has been investigated in clinical trials for its safety and efficacy in patients with advanced or relapsed hormone-responsive breast cancer[1][2][3].

Other names: tremelimumab in combination with exemestane

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on exemestane + tremelimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on exemestane + tremelimumab.

Explore the full profile